Glycoengineering bioconjugate vaccines, therapeutics, and diagnostics in E. coli

Christian M. Harding, Mario F. Feldman

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


The first, general glycosylation pathway in bacteria, the N-linked glycosylation system of Campylobacter jejuni, was discovered two decades ago. Since then, many diverse prokaryotic glycosylation systems have been characterized, including O-linked glycosylation systems that have no homologous counterparts in eukaryotic organisms. Shortly after these discoveries, glycosylation pathways were recombinantly introduced into E. coli creating the field of bacterial glycoengineering. Bacterial glycoengineering is an emerging biotechnological tool that harnesses prokaryotic glycosylation systems for the generation of recombinantly glycosylated proteins using E. coli as a host. Over the last decade, as our understanding of prokaryotic glycosylation systems has advanced, so too has the glycoengineering toolbox. Currently, glycoengineering utilizes two broad approaches to recombinantly glycosylate proteins, both of which can generate N-or O-linkages: oligosaccharyltransferase (OTase)-dependent and OTase-independent. This review discusses the applications of these bacterial glycoengineering techniques as they relate to the development of glycoconjugate vaccines, therapeutic proteins, and diagnostics.

Original languageEnglish
Article numbercwz031
Pages (from-to)519-529
Number of pages11
Issue number7
StatePublished - Jul 1 2019


  • E. coli
  • bioconjugate
  • glycoengineering
  • glycosyltransferase
  • oligosaccharyltransferase

Fingerprint Dive into the research topics of 'Glycoengineering bioconjugate vaccines, therapeutics, and diagnostics in E. coli'. Together they form a unique fingerprint.

Cite this